Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

NCT02523014 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT02523014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02523014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
September 28, 2015
Completion date
January 31, 2028
Enrollment
124 (estimated)
Sites
784

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial meningioma, nf2 gene mutation, recurrent meningioma